This week in clinical pharmacology:
The FDA approves eravacycline for abdominal infections and doravirine for HIV. Low-dose rivaroxaban does not lower cardiovascular risk in HF without atrial fibrillation, tafamidis demonstrates efficacy in transthyretin amyloidosis, and brexanolone shows promise in post-partum depression.
- September 4th, 2018
Continue reading “Pharmacology News Digest, September 4th, 2018”